Piper Sandler analyst Adam Maeder downgraded Inari Medical to Neutral from Overweight with a price target of $55, down from $85.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NARI:
- Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
- Inari Medical initiated with a Buy at Needham
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
- Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
- Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M
